Nov 18, 2019
New Sickle Cell Drug With Oklahoma Roots Receives FDA Approval
Nov 15, 2019
New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
Nov 15, 2019
FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease
Nov 04, 2019
Sickle Cell Disease Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Jan 08, 2019
Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
Dec 01, 2018
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
Nov 28, 2018
Hillhurst Biopharmaceuticals Receives Phase 2 SBIR Funding For Clinical Development Of HBI-002 For Prevention Of Vaso-Occlusive Crises in Sickle Cell Disease
Oct 09, 2018
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
May 23, 2018
Sickle Cell Anemia: Global Drug Market Outlook to 2024 - A $350 Million Market Opportunity
Dec 13, 2017
Prolong Pharmaceuticals Announces Completion of Enrollment in Phase II Study of SANGUINATE® in the Treatment of Sickle Cell Disease Patients with Vaso-Occlusive Crisis in an Ambulatory Setting
Dec 11, 2017
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study